Morgan Stanley Reiterates “$15.00” Price Target for Teva Pharmaceutical Industries Limited (TEVA)

Morgan Stanley set a $15.00 price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report published on Thursday. The brokerage currently has an underweight rating on the stock.

Several other research analysts have also commented on the company. Wells Fargo & Company reiterated a market perform rating on shares of Teva Pharmaceutical Industries Limited in a report on Thursday. Cowen and Company reiterated a market perform rating and set a $18.00 price target (down previously from $30.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Maxim Group reiterated a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a strong sell rating to a hold rating in a report on Wednesday. Finally, Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Five equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Hold and an average target price of $27.63.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 15.94 on Thursday. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.85. The company’s 50-day moving average is $16.91 and its 200-day moving average is $26.76. The stock’s market cap is $16.20 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm earned $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Morgan Stanley Reiterates “$15.00” Price Target for Teva Pharmaceutical Industries Limited (TEVA)” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://transcriptdaily.com/2017/10/08/morgan-stanley-reiterates-15-00-price-target-for-teva-pharmaceutical-industries-limited-teva.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.13%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Several institutional investors have recently made changes to their positions in the company. Capital Research Global Investors grew its position in shares of Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after buying an additional 6,115,853 shares in the last quarter. Northern Cross LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after buying an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Teva Pharmaceutical Industries Limited by 2.5% during the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after buying an additional 311,894 shares in the last quarter. 56.77% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply